December 14, 2017

WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease

Dec 14, 2017 Wilson Therapeutics AB (publ), today announced that the U.S. Food and Drug Administration (FDA) has granted WTX101 Fast Track designation for the treatment of Wilso...
Read more
December 13, 2017

Strongbridge Biopharma plc Added to the NASDAQ Biotech Index

DUBLIN, Ireland and TREVOSE, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on t...
Read more
December 13, 2017

BONESUPPORT™ ACHIEVES AIM OF RECRUITING 136 PATIENTS INTO THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by t...
Read more
December 12, 2017

Orexo discloses more information about the improved market access position for Zubsolv® US in 2018

Uppsala, Sweden – December 12, 2017 - Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublin...
Read more
December 11, 2017

HealthTech company Doctrin raises SEK 100 million in financing round led by Capio and HealthCap to fuel further expansion and AI development

HealthTech company Doctrin raises SEK 100 million in a Series A round led by healthcare provider Capio and Life Science fund HealthCap, with Inbox Capital and Norrsken Founda...
Read more
December 11, 2017

Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems f...
Read more
December 11, 2017

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that cli...
Read more
December 11, 2017

Betalutin® shows strong clinical profile in relapsed/refractory indolent NHL and follicular lymphoma

Updated data reported at the 59th Annual American Society of Hematology (ASH) meeting  Oslo, Norway, 11 December 2017 Nordic Nanovector ASA (OSE: NANO) has presented updated...
Read more
December 10, 2017

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Stockholm – December 10th, 2017 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the Americ...
Read more
December 9, 2017

Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Stockholm – December 9th, 2017 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the o...
Read more